对危及生命的肝癌转移患者使用帕妥珠单抗和曲妥珠单抗双重抗her2阻滞治疗的安全性如何?

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2020-09-04 DOI:10.2217/bmt-2020-0019

V. Rossi, L. Grillo, F. D. Cesare, E. Saraco, F. Scardamaglia, F. Svegliati, A. Cortese, L. Vigna

{"title":"对危及生命的肝癌转移患者使用帕妥珠单抗和曲妥珠单抗双重抗her2阻滞治疗的安全性如何?","authors":"V. Rossi, L. Grillo, F. D. Cesare, E. Saraco, F. Scardamaglia, F. Svegliati, A. Cortese, L. Vigna","doi":"10.2217/bmt-2020-0019","DOIUrl":null,"url":null,"abstract":"Aim: We report a case of a young woman who presented with HER2+ metastatic breast cancer and visceral crisis to asses safety and effectiveness of dual anti-HER2 plus chemotherapy. Patients & methods/materials & methods: At the time of advanced breast cancer diagnosis, the patient presented in scanty clinical condition with severe liver function tests elevation. First-line chemotherapy based on pertuzumab-trastuzumab plus weekly paclitaxel at 50% reduced dose due to liver dysfunction was administered. Results: Improvement and normalization of liver function tests and patient’s clinical condition was recorded in less than 2 months. Computed tomography revealed a partial remission of liver metastasis. Conclusions: Early initiation of standard HER2 target therapies outweigh the risks of toxicities and can be successfully used also in patients with life-threatening liver breast cancer metastasis.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2020-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0019","citationCount":"2","resultStr":"{\"title\":\"How safe is it to administer dual anti-HER2 block with pertuzumab and trastuzumab on a patient with life-threatening liver breast cancer metastasis?\",\"authors\":\"V. Rossi, L. Grillo, F. D. Cesare, E. Saraco, F. Scardamaglia, F. Svegliati, A. Cortese, L. Vigna\",\"doi\":\"10.2217/bmt-2020-0019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: We report a case of a young woman who presented with HER2+ metastatic breast cancer and visceral crisis to asses safety and effectiveness of dual anti-HER2 plus chemotherapy. Patients & methods/materials & methods: At the time of advanced breast cancer diagnosis, the patient presented in scanty clinical condition with severe liver function tests elevation. First-line chemotherapy based on pertuzumab-trastuzumab plus weekly paclitaxel at 50% reduced dose due to liver dysfunction was administered. Results: Improvement and normalization of liver function tests and patient’s clinical condition was recorded in less than 2 months. Computed tomography revealed a partial remission of liver metastasis. Conclusions: Early initiation of standard HER2 target therapies outweigh the risks of toxicities and can be successfully used also in patients with life-threatening liver breast cancer metastasis.\",\"PeriodicalId\":43086,\"journal\":{\"name\":\"Breast Cancer Management\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2020-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/bmt-2020-0019\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/bmt-2020-0019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2020-0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

摘要

目的:我们报告了一例年轻女性HER2+转移性乳腺癌和内脏危象，以评估双重抗HER2+化疗的安全性和有效性。患者与方法/材料与方法:患者在诊断为晚期乳腺癌时，临床状况不佳，肝功能检查结果严重升高。一线化疗基于帕妥珠单抗-曲妥珠单抗加上每周紫杉醇减少50%剂量由于肝功能障碍。结果:在不到2个月的时间内，肝功能检查和患者临床情况均有改善和正常化。计算机断层扫描显示肝转移部分缓解。结论:早期开始标准HER2靶向治疗的风险大于毒性，并且可以成功地用于危及生命的肝乳腺癌转移患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

How safe is it to administer dual anti-HER2 block with pertuzumab and trastuzumab on a patient with life-threatening liver breast cancer metastasis?

Aim: We report a case of a young woman who presented with HER2+ metastatic breast cancer and visceral crisis to asses safety and effectiveness of dual anti-HER2 plus chemotherapy. Patients & methods/materials & methods: At the time of advanced breast cancer diagnosis, the patient presented in scanty clinical condition with severe liver function tests elevation. First-line chemotherapy based on pertuzumab-trastuzumab plus weekly paclitaxel at 50% reduced dose due to liver dysfunction was administered. Results: Improvement and normalization of liver function tests and patient’s clinical condition was recorded in less than 2 months. Computed tomography revealed a partial remission of liver metastasis. Conclusions: Early initiation of standard HER2 target therapies outweigh the risks of toxicities and can be successfully used also in patients with life-threatening liver breast cancer metastasis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.